Cystic Fibrosis Questionnaire Revised

Related by string. * cystic : cystic fibrosis Tay Sachs . cystic fibrosis CF . cystic fibrosis transmembrane conductance / fibrosis : cystic fibrosis inflammation autoimmune . idiopathic pulmonary fibrosis IPF . Fibrosis / Questionnaires . questionnaires : census questionnaire . Difficulties Questionnaire / Revising . REVISED : Ohio Revised Code . Nevada Revised Statutes * *

Related by context. Frequent words. (Click for all words.) 62 PANSS 62 Secondary endpoints included 61 Secondary endpoints include 60 EQ 5D 60 Montgomery Asberg Depression 60 Main Outcome Measures 59 Negative Syndrome 59 Severity Index PASI 59 Psoriasis Area 59 Alzheimer Disease Assessment 58 Prognostic 58 dyspnoea 58 logistic regression analysis 58 ADAS cog 57 Disease Activity 57 Health Assessment Questionnaire 57 HRQoL 57 estimated glomerular filtration 56 Visual Analog Scale 56 erythrocyte sedimentation rate 56 Outcomes Study 56 Natural Catastrophe Stress 56 sensitivity specificity 56 DAS# [002] 55 International Prostate Symptom 55 QTc prolongation 55 Patient Satisfaction 55 QoL 54 Venous Thromboembolism 54 MADRS 54 Solid Tumors 54 glomerular filtration rate 54 Global Impression 54 hemoglobin A1c HbA1c 54 Angiographic 54 clinically meaningful improvement 54 serum potassium 54 C Reactive Protein 54 Hemodynamic 54 Patient Outcomes 54 SpO2 54 univariate analysis 54 HRQL 54 Medication Errors 54 symptom severity 54 Comorbidity 54 myocardial perfusion 54 WOMAC 54 Unified Parkinson Disease 54 univariate 54 Preoperative 53 carotid intima media 53 Blood Glucose 53 multivariate logistic regression 53 Thrombolysis 53 APTIVUS r 53 QualityMetric 53 PHQ 9 53 HbA1C 53 platelet reactivity 53 UPDRS 53 biochemical recurrence 53 creatinine clearance 53 RECIST criteria 53 Significantly Reduces 53 0 document.write 53 HRQOL 53 multivariate analyzes 53 exhaled nitric oxide 53 D dimer 53 heparin induced thrombocytopenia 53 MammaPrint R 52 extrapyramidal symptoms 52 p = .# [002] 52 Secondary endpoints 52 sustained virological response 52 Atopic Dermatitis 52 P = .# 52 induration 52 CDAI 52 Spirometry 52 Adalimumab 52 IPSS 51 Therein lurks 51 fasting insulin 51 glycated hemoglobin 51 Bioavailability 51 T2DM 51 apolipoprotein B 51 achieved statistical significance 51 statistically significant p = 51 Expanded Disability Status 51 logistic regression 51 Clinical Documentation 51 Study Demonstrates 51 RU EUROPE EEU EMRG 51 % #gt 51 By Thomas Gryta 50 immunohistochemical 50 posttreatment 50 Depressive symptoms

Back to home page